ASX ANNOUNCEMENT

29 October 2026

Quarterly Activities Report and Appendix 4C

Vectus Biosystems Limited (ASX:VBS) (Vectus or the Company) is pleased to present its Quarterly Activities Report and Quarterly Cash Flow Report – Appendix 4C for the period ended 30 September 2026.

HIGHLIGHTS

- US Food and Drug Administration (FDA) granted Vectus' request for a pre-Investigational New Drug (pre-IND) Type B meeting regarding the proposed development programme for VB0004 in idiopathic pulmonary fibrosis (IPF).
- FDA written responses are expected by mid-November 2026 to inform the next stages of clinical and regulatory development.
- Cardinal Health Regulatory Services (CHRS) was appointed as the Company's US Regulatory Agent to prepare and facilitate FDA-facing communications, interactions and submissions.

FDA Grants Pre-IND Meeting Request for VB0004 in IPF

During the quarter, Vectus progressed the US regulatory pathway for its lead compound, VB0004, with the FDA granting the Company's request for a pre-IND Type B meeting regarding its proposed development programme in IPF. The interaction will take the form of written responses from the FDA, which are expected to be received by mid-November 2026. This feedback will provide formal guidance on the proposed programme and help inform the next stages of VB0004's clinical and regulatory development. Following the granting of the request, Vectus and its US Regulatory Agent, CHRS, commenced the finalisation of the meeting package for submission to the FDA.

VB0004 is the Company's first-in-class oral vasoactive intestinal peptide-mimetic and natriuretic peptide receptor C-agonist in development for the treatment of IPF. Vectus has completed a Phase Ia clinical study in healthy volunteers, establishing a favourable safety and pharmacokinetic profile. The pre-IND interaction represents an important step in establishing the foundation for future clinical development in the US. IPF remains the initial focus for VB0004, addressing a progressive and often fatal lung disease with significant unmet medical need.

Appointment of CHRS as US Regulatory Agent

In July 2026, the Company formally engaged CHRS as its US Regulatory Agent, providing a primary point of contact for all FDA-facing regulatory activities for VB0004 and, potentially, other pipeline assets as they advance. Under the engagement, CHRS will facilitate and prepare FDA-facing communications, interactions and submissions on behalf of Vectus. The scope includes the Orphan Drug Designation Request, pre-IND communications and the IND application for VB0004 in IPF.

CHRS is a US regulatory affairs consultancy with expertise in FDA submissions and drug development strategies. Its appointment supports the Company's preparations for a US

development programme and the progression of VB0004 through the required regulatory processes.

Conference and Event Participation

In August 2026, Vectus' Chief Executive Officer and Chief Technology Officer (CEO & CTO), Dr Tara Speranza, presented at the Bioshares Biotech Summit to a range of investors and other attendees from Australia and New Zealand's biotechnology community. Dr Speranza shared the Company's development strategy for VB0004 with the attendees, while also conducting numerous one-on-one meetings with interested parties.

Financial Update

Payments for commercialisation, patents, staff costs and clinical development during the quarter amounted to $142,000. Net cash used in operating activities was $309,000. The 2025-26 research and development cash refund of $208,000 was received from the Australian Taxation Office in October 2026. Cash-on-hand at 30 September 2026 was $410,000, compared to $719,000 at 30 June 2026.

Payments to related parties and key management personnel, and their associates, during the September 2026 quarter, as detailed in Section 6 of the accompanying Appendix 4C, totalled $75,000, and comprised the salary of the CEO & CTO of $45,000 and fees of $30,000 were paid to Regional Corporate Services Pty Ltd (of which Non-Executive Director Maurie Stang is a director) for corporate services, including cost re-imbursement for information technology, human resources and accounting services, in line with budget.

Ronald Shnier
Chairman

Tara Speranza
CEO & CTO
info@vectusbiosystems.com.au

This announcement was authorised by the Board of Directors

About Vectus Biosystems Limited

Vectus Biosystems Limited (ASX:VBS) is an Australian clinical-stage biotechnology company developing novel therapies for fibrotic diseases, with an initial focus on advancing its lead compound, VB0004, for the treatment of idiopathic pulmonary fibrosis (IPF), a progressive, and often fatal, lung disease with significant unmet medical need. VB0004 is a first-in-class antifibrotic candidate that has demonstrated the ability to reverse established fibrosis in preclinical models, and has successfully completed Phase Ia clinical studies, establishing a favourable safety and pharmacokinetic profile.

Beyond IPF, the Company is advancing a broader pipeline of antifibrotic assets targeting cardiovascular, renal and liver fibrosis, leveraging a platform approach to address diseases driven by pathological tissue scarring. The commercial potential of the platform has been externally validated through a licensing agreement with an international biotechnology company for one of Vectus' renal fibrosis assets, showing a pathway for potential future milestone and royalty revenues.

The Company will continue its clinical development with an ambition to create shareholder value through the advancement, partnering and commercialisation of innovative therapies that address significant unmet needs in fibrotic disease.

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity

Vectus Biosystems Limited

ABN	Quarter ended ("current quarter")
54 117 526 137	**30 September 2026**

Consolidated statement of cash flows

	1 Cash flows from operating activities	**Current quarter $A'000**	**Year to date (3 months) $A'000**
1.1	Receipts from customers	-	-
1.2	Payments for		
	(a) patent and research expenses	(103)	(103)
	(b) staff costs and directors' fees	(39)	(39)
	(c) occupancy cost	-	-
	(d) corporate overheads	(97)	(97)
	(e) legal and professional fees	(48)	(48)
	(f) other operating items	(32)	(32)
1.3	Dividends received	-	-
1.4	Interest and other items of a similar nature received	10	10
1.5	Interest and other costs of finance paid	-	-
1.6	Income tax refund received (including R&D tax offset)	-	-
1.7	Government grants and tax incentives	-	-
1.8	Others (provide details if material)	-	-
1.9	**Net cash from / (used in) operating activities**	(309)	(309)

Consolidated statement of cash flows	Current quarter $A'000	Year to date (3 months) $A'000
2 Cash flows from investing activities		
2.1 Payments to acquire or for:		
(a) entities	-	-
(b) businesses	-	-
(c) property, plant and equipment	-	-
(d) investments	-	-
(e) intellectual property	-	-
(f) other non-current assets	-	-
2.2 Proceeds from disposal of:		
(a) entities	-	-
(b) businesses	-	-
(c) property, plant and equipment	-	-
(d) investments	-	-
(e) intellectual property	-	-
(f) other non-current assets	-	-
2.3 Loans to other entities	-	-
2.4 Dividends received (see note 3)	-	-
2.5 Other (provide details if material)	-	-
2.6 Net cash from / (used in) investing activities	-	-
3 Cash flows from financing activities		
3.1 Proceeds from issues of equity securities (excluding convertible debt securities)	-	-
3.2 Proceeds from issue of convertible debt securities	-	-
3.3 Proceeds from exercise of options	-	-
3.4 Transaction costs related to issues of equity securities or convertible debt securities	-	-
3.5 Proceeds from borrowings	-	-
3.6 Repayment of borrowings	-	-
3.7 Transaction costs related to loans and borrowings	-	-
3.8 Dividends paid	-	-
3.9 Other (provide details if material)	-	-
3.10 Net cash from / (used in) financing activities	-	-

Consolidated statement of cash flows		Current quarter $A'000	Year to date (3 months) $A'000
4	**Net increase / (decrease) in cash and cash equivalents for the period**		
4.1	Cash and cash equivalents at beginning of period	719	719
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(309)	(309)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	-	-
4.4	Net cash from / (used in) financing activities (item 3.10 above)	-	-
4.5	Effect of movement in exchange rates on cash held	-	-
4.6	**Cash and cash equivalents at end of period**	**410**	**410**

5	**Reconciliation of cash and cash equivalents**		
	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter $A'000	Previous quarter $A'000
5.1	Cash on hand and at bank	410	719
5.2	Term Deposits	-	-
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
5.5	**Cash and cash equivalents at end of quarter (item 4.6)**	**410**	**719**

6	**Payments to related parties of the entity and their associates**	**Current quarter $A'000**
6.1	Aggregate amount of payments to related parties and their associates included in item 1	75
6.2	Aggregate amount of payments to related parties and their associates included in item 2	-

7 Financing facilities

Note: The term "facility' includes all forms of financing arrangements available to the entity

Add notes as necessary for an understanding of the sources of finance available to the entity

		Total facility $A'000	Amount drawn $A'000
7.1	Loan facilities	450	450
7.2	Credit standby arrangements	-	-
7.3	Other (please specify)	-	-
7.4	Total financing facilities	450	450
7.5	Unused financing facilities available at quarter end		-

7.6 Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.

The loan facility of up to $450,000 has been entered into with Director Maurie Stang, which has been fully drawn down. This facility can be repaid, without penalty, if Vectus secures alternative funding. The drawdown of the loan is to be repaid from future receipts from the ATO of research and development (R&D) cash-back or from other funds received.

8 Estimated cash available for future operating activities	**$A'000**
8.1 Net cash from / (used in) operating activities (item 1.9)	(309)
8.2 Cash and cash equivalents at quarter end (item 4.6)	410
8.3 Unused finance facilities available at quarter end (item 7.5)	-
8.4 Total available funding (item 8.2 + item 8.3)	410
8.5 Estimated quarters of funding available (item 8.4 divided by item 8.1)	1.33

8.6 If item 8.5 is less than 2 quarters, please provide answers to the following questions:

8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?

Expenditure has fallen significantly in recent quarters. Following the completion of the previous Phase Ia trial, Vectus has reduced its staff and consultant numbers, with the CEO now covering both executive and technical roles, and moved to lower cost premises. With no trial currentlty running, spending is focused on IP activities and VB0004 regulatory work that adds value to the asset.

8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?

The Company received its 2025-26 R&D cash refund of $208,000 from the ATO in October 2026. Vectus continues to evaluate a number of options to address its future capital requirements, and is actively pursuing licensing opportunities, which, if successful, may provide upfront payments to the Company and annuity revenue going forward. The Company may gain additional liquidity through the sale of some of its XORTX shares.

8.6.3 Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?

The Company expects to be able to continue its operations, and to meet its business objectives, based on its reduced overheads and the matters outlined in 8.6.2.

Compliance statement

1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.

2 This statement gives a true and fair view of the matters disclosed.

Date: **29 October 2026**

Authorised for release to the market by the Vectus Board of Directors.

Notes:

1 This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules isencouraged to do so.

2 If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, AASB 107: Statement of Cash Flows apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.

3 Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.

4 If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [name of board committee – e.g. Audit and Risk Committee]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".

5 If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's Corporate Governance Principles and Recommendations, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.